Macrophage PRMT9 Limits Myocardial Infarction Damage in Mice

Modulating the Inflammatory Cascade in Myocardial Recovery

The clinical management of acute myocardial infarction has evolved significantly, yet ischemia-reperfusion injury (tissue damage caused when blood supply returns to the heart after a period of oxygen deprivation) remains a primary driver of post-ischemic morbidity [1, 2]. Following the initial event, the myocardium undergoes an intense inflammatory response where macrophages play a dual role, transitioning between pro-inflammatory M1-like states that exacerbate tissue damage and reparative M2-like states [3, 4]. Excessive activation of the Janus kinase and signal transducer and activator of transcription (JAK-STAT) system, a signaling pathway that communicates external chemical signals to the cell nucleus, can lead to persistent inflammation and adverse ventricular remodeling [5, 2]. Recent advances in cardiovascular epigenetics (the study of chemical modifications that regulate gene expression without altering the DNA sequence) suggest that post-translational protein methylation is a critical regulator of these inflammatory phenotypes [6, 3]. A new study identifies that protein arginine methyltransferase 9 (PRMT9) facilitates the symmetric dimethylation and autophagic degradation of STAT1, a process that suppressed excessive M1-like macrophage responses and reduced infarct size in experimental models [3]. Understanding these enzymatic triggers is essential for developing targeted interventions to transition the heart from a destructive to a reparative state.

PRMT9 Expression and Macrophage Polarization

The pathophysiology of acute myocardial infarction involves a complex immune response where M1-like macrophages exacerbate myocardial injury by excessively secreting inflammatory cytokines. These pro-inflammatory cells intensify the initial tissue damage, contributing to larger infarct sizes and poorer functional outcomes. To identify the molecular drivers of this response, the researchers utilized the myocardial infarction dataset GSE166780 (a public repository of genomic data used to identify gene expression patterns) to investigate the correlation between the expression of protein arginine methyltransferase 9 (PRMT9) in monocytes and macrophages and the progression of cardiac injury. This bioinformatic approach allowed the team to screen for enzymes that might naturally regulate the intensity of the post-infarct immune response.

To validate these findings in a clinical context, the study analyzed peripheral blood mononuclear cells (a diverse population of immune cells including monocytes and lymphocytes) obtained from healthy individuals and patients with myocardial infarction. The researchers discovered that PRMT9 was highly expressed in both murine and human peripheral blood mononuclear cells during the early stages of myocardial infarction. This upregulation suggests that PRMT9 serves as a critical early-phase regulator in the systemic immune response to cardiac ischemia, potentially acting as a natural brake on the inflammatory cascade that follows coronary occlusion. For the practicing clinician, this identifies PRMT9 as a potential biomarker for the endogenous inflammatory control mechanisms activated immediately following an ischemic event.

Impact of PRMT9 on Infarct Size and Cardiac Function

To determine the causal role of PRMT9 in post-ischemic recovery, the researchers utilized macrophage-specific Prmt9 knockout mice, a genetic model where the gene encoding protein arginine methyltransferase 9 is selectively deleted only within the macrophage lineage. This approach allowed the team to isolate the specific influence of this enzyme on the immune response without the confounding effects of systemic gene deletion. In parallel, the study employed macrophage-specific overexpression adeno-associated virus vectors (engineered viral delivery systems designed to increase the production of a specific protein within target cells) to artificially elevate PRMT9 levels in murine models. These dual experimental arms provided a controlled environment to observe how varying concentrations of the enzyme influence the heart's healing process after a myocardial infarction.

The loss of this regulatory enzyme led to a significant physiological decline in the experimental models. The researchers observed that PRMT9 deficiency in murine models enhanced M1-like polarization, shifting the macrophage population toward a more aggressive, pro-inflammatory state that secretes high levels of cytokines. This shift resulted in a sustained inflammatory environment that exacerbated cardiac damage, characterized by increased tissue necrosis and a failure to transition into the reparative phase of healing. These findings suggest that without sufficient PRMT9 activity, the heart is unable to restrain the destructive inflammatory signaling that follows an acute ischemic event, leading to more extensive myocardial loss.

Conversely, increasing the presence of the enzyme yielded protective effects on the myocardium. The study found that PRMT9 overexpression in macrophages reduced infarct size (the total area of dead heart muscle) and accelerated inflammation resolution after myocardial infarction. By promoting a faster transition away from the inflammatory M1-like state, the treatment limited the expansion of the necrotic zone and facilitated earlier tissue stabilization. Furthermore, PRMT9 overexpression in macrophages improved cardiac function following the infarction, as measured by the heart's ability to maintain output and contractility. These results indicate that modulating PRMT9 levels could potentially preserve viable myocardium and maintain the heart's pumping capacity in the clinical setting, offering a potential target for limiting the progression of heart failure post-infarction.

The STAT1 Degradation Mechanism

The researchers elucidated the intracellular pathways governing these observations through a combination of flow cytometry, transcriptome analysis (the study of the complete set of RNA transcripts produced by the genome), immunoprecipitation/mass spectrometry analysis, and functional experiments. While most protein arginine methyltransferases (PRMTs) primarily regulate protein function via asymmetric dimethylation, the study focused on the distinct biochemical activity of PRMT9, which specifically performs symmetric dimethylation (the addition of two methyl groups to the same nitrogen atom on an arginine residue). This unique enzymatic activity proved essential for modulating the immune response, as PRMT9-catalyzed methylation plays a critical role in STAT1 (signal transducer and activator of transcription 1)-mediated macrophage polarization. Specifically, the researchers found that PRMT9 directly binds to STAT1 and facilitates its symmetric dimethylation at residues R588 and R736, a modification that alters the stability of this transcription factor.

The downstream consequences of this methylation involve a precise cellular disposal system. The study demonstrated that PRMT9-mediated symmetric dimethylation facilitates STAT1 ubiquitination, which is the biochemical process of marking a protein for degradation by attaching a small regulatory protein called ubiquitin. Once tagged, the ubiquitinated STAT1 is recognized by SQSTM1/p62 (sequestosome-1) and NDP52/CALCOCO2 (nuclear dot protein 52), two cargo receptors that direct proteins toward the cell's internal recycling machinery. This recognition facilitates STAT1-selective autophagic degradation, the targeted breakdown of proteins within the cell's lysosomal system. By clearing STAT1 from the cytoplasm, this degradation pathway suppresses excessive M1-like macrophage responses, effectively dampening the pro-inflammatory signaling that would otherwise exacerbate myocardial injury. This mechanism highlights a specific intracellular pathway that could be targeted to modulate immune cell behavior without broad immunosuppression.

Pharmacological Rescue via STAT1 Inhibition

The identification of the PRMT9-STAT1 pathway provides a specific target for therapeutic intervention aimed at limiting the inflammatory damage that follows an acute coronary event. To test the clinical viability of modulating this axis, the researchers investigated whether the detrimental effects of PRMT9 deficiency could be reversed using a pharmacological agent. They focused on fludarabine, a purine analog and chemotherapeutic agent currently used in clinical practice, which is known to function as a specific inhibitor of STAT1 (signal transducer and activator of transcription 1). By utilizing a drug already approved for human use in other indications, the study sought to bridge the gap between the molecular discovery of protein arginine methyltransferase 9 (PRMT9) function and potential bedside applications.

The experimental results demonstrated that the administration of fludarabine mitigated the exacerbation of post-myocardial infarction injury induced by PRMT9 deletion in macrophages. In the absence of the PRMT9 enzyme, which normally facilitates the degradation of STAT1 to suppress inflammation, the heart typically suffers from increased M1-like macrophage activity and larger infarct sizes. However, the researchers found that pharmacological inhibition of STAT1 effectively rescued this phenotype, reducing the severity of myocardial damage despite the lack of PRMT9. These findings suggest that targeting the STAT1-mediated inflammatory response may serve as a viable strategy for adjunctive therapy during the early stages of myocardial infarction recovery, potentially offering a method to limit tissue loss and improve cardiac function in patients. For clinicians, this research underscores the potential for repurposing existing agents like fludarabine to manage the acute inflammatory phase of myocardial infarction.

References

1. Zhang M, Liu Q, Meng H, et al. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-023-01688-x

2. Zhang Q, Wang L, Wang S, et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-00925-z

3. Bai X, Ren R, Yuan J, et al. Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1.. Circulation. 2026. doi:10.1161/CIRCULATIONAHA.125.076101

4. Kong P, Cui Z, Huang X, Zhang D, Guo R, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-00955-7

5. Guo Q, Jin Y, Chen X, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01757-9

6. Shi Y, Zhang H, Huang S, et al. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01055-2